Benifiting from 40 years of expertise on transfusion medicine with a strong knowledge on platelets and on pathogen inactivation, Maco Pharma Biotherapy developed a range of human platelet lysates : MultiPL', to expand stem cells and other cell types.
Results consistency for stem cell expansion in defined, standardised and xeno-free conditions represents a major challenge for cell therapy and advanced therapy medicinal products.
Our range of Human Platelet Lysates
For clinical use
MultiPL’ by Macopharma is a commercial range of human platelet lysate that supports the expansion of different cell types. It is validated with mesenchymal stem cells and it can be used with other cell types such as fibroblasts, keratinocytes and natural killers.
The full MultiPL' range is produced from qualified donors and platelets intended for human transfusion allowing a safety and traceability of our products. MultiPL' is rich in proteins and growth factors required for cell proliferation. MultiPL' is a safe, efficient, and standardised alternative to fetal bovine serum. For more information about Platelet Lysate, you can check our Bibliography.
MultiPL’ is manufactured in a certified ISO 13485 facility in France. All steps of the manufacturing process are performed in a closed system and by trained operators in a controlled atmosphere area.
An efficient, safe and standardised supplement to expand multiple cell types
- Enhanced expansion
- Reduced supplementation
- Manufactured and tested in line with quality system of pharmaceutical company
- Produced in large batches
MultiPL' is divided in two sub-ranges with two distinct compositions:
- MultiPL'30 and MultiPL'100
- Virally inactivated, MultiPL'30i and MultiPL'100i
A unique range to optimise the chance to find the ideal supplement for your cells and your protocols.
MultiPL'30 and MultiPL'100
First, Maco Pharma developed MultiPL'30 composed by 30% plasma and 70% additive solution. Then Maco Pharma widened its Maco Pharma range with MultiPL'100. Made of 100% plasma , MultiPL'100 presents different features than MultiPL'30. Thereby, testing both our products double your changes of finding the ideal supplement for your cell.
|Reference||Volume (mL)||Source||Composition||Storage conditions||Shelf life|
|50||Buffy Coat platelet concentrates||30% plasma & 70% additive solution||Between -80°C and -20°C protected from light||30 months|
|Aphaeresis platelet concentrates||100% plasma||24 months|
*This product contains human source material and must be treated as potentially infectious. Despite all testing, proper safety precautions for potentially infectious agents must be taken.
- Derived from screened normal human donor platelets
- Sterilised by 0.2 µm filtration
- Produced in large batch sizes (10 L)
- Stored in freezing bag
- Rich in proteins and growth factors (PDGF-AB, IGF-1, EGF, VEGF and bFGF)
- For clinical
- Validated for BM-MSC culture (see “Performance”)
- Increased cell growth kinetics
- Xeno-free media supplement (no animal proteins)
- Minimal lot to lot variation
- Reduced supplementation in comparison with FBS (fetal bovine serum)
- Eliminates the need for bFGF
- Available in optimised small volume
- Lot reservation available
MultiPL’ enhances MSC proliferation compared to FBS
Dose effect on proliferation of human bone marrow-mesenchymal stem cells (hBM-MSCs) cultured in MEMa supplemented with FBS or MultiPL’30/MultiPL'100 at doses ranging from 2,5% to 10% and 2UI/mL heparin. hBM-MSCs were seeded at 2000c/cm2 in 6-well plates and cultured during 8 days.
MultiPL' maintains the differentiation potential of hBMC-MSC.
Differentiation potential of human bone marrow-mesenchymal stem cells (hBM-MSCs) expanded in 10% FBS or 8 % MultiPL'30 (A) OR multiPL"100 (B).
After expansion, hBM-MSCs were cultured in presence of specific differentiation media during 14 and 21 days to induce adipogenic and osteogenic differentiation, respectively
MultiPL' maintains hBM-MSC phenotype
Flow cytometry analysis of human bone marrow-mesenchymal stem cells expanded in 10% FBS or 8% MultiPL’30/ MultiPL’100 .
After expansion, hBM-MSCs were incubated with either PE-conjugated monoclonal antibodies or isotype control.